Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC
ConclusionsThis study has identified a truncated dosing regimen and recommended phase II dose of demcizumab (5 mg/kg q3-weekly ×4) for subsequent clinical evaluation in combination with standard carboplatin and pemetrexed chemotherapy. NCT01189968.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
More News: Alimta | Brain | Brain Cancers | Cancer | Cancer & Oncology | Cardiology | Chemotherapy | Congestive Heart Failure | Genetics | Heart | Heart Failure | Hypertension | Lung Cancer | Neurology | Non-Small Cell Lung Cancer | Pulmonary Hypertension | Stem Cell Therapy | Stem Cells | Study | Toxicology